Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Plaque Psoriasis
Interventions: IDP-122 Lotion, IDP-122 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Santa Ana, California • Boynton Beach, Florida • Clearwater, Florida + 12 more

Conditions: Psoriasis
Interventions: Shave Biopsy of Psoriasis Lesion; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Plaque Psoriasis, Psoriasis Vulgaris
Interventions: Taclonex Ointment and Hydrogel Patch, Taclonex Ointment; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriatic Arthritis (PsA)
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 55
States / cities: Anniston, Alabama • Fullerton, California • Huntington Beach, California + 50 more

Conditions: Parapsoriasis
Interventions: Apremilast, Placebo, Placebo-Apremilast; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Birmingham, Alabama • Fremont, California • Los Angeles, California + 21 more

Conditions: Psoriasis
Interventions: BMS-986165, Placebo for BMS-986165; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Irvine, California • San Diego, California • Ocala, Florida + 13 more

Conditions: Arthritis, Rheumatoid, Crohn Disease, Psoriasis
Interventions: Infliximab (Remicade); Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: Not listed
Enrollment: 2,971 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 100
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more

Conditions: Psoriasis
Interventions: 210mg Brodalumab, 140mg Brodalumab, Ustekinumab, Placebo; Biological
Lead sponsor: MedDerm Associates; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Psoriasis
Interventions: Ustekinumab, Abatacept, UST Placebo, ABA Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 5 more

Conditions: Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo, Apremilast; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 24
States / cities: Mountain Brook, Alabama • Sacramento, California • Whittier, California + 21 more

Conditions: Psoriasis
Interventions: teplizumab; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Portland, Oregon

Conditions: Psoriasis Vulgaris
Interventions: Phototherapy; Device
Lead sponsor: Mary Sullivan-Whalen; Other
Eligibility: 14 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis, Pregnancy
Interventions: Not listed
Lead sponsor: Genentech, Inc.; Industry
Eligibility: Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Moderate to Severe Psoriasis
Interventions: Intralesional Alefacept; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Plaque Psoriasis
Interventions: Placebo, ABT-874; Drug · Biological
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 1,465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 93
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 76 more

Conditions: Chronic Plaque Psoriasis
Interventions: Alefacept; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 19
States / cities: Irvine, California • San Francisco, California • Santa Monica, California + 15 more

Conditions: Psoriasis
Interventions: GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 18
States / cities: San Diego, California • North Logan, Connecticut • Miami, Florida + 15 more

Conditions: Psoriasis
Interventions: etanercept; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Plaque Psoriasis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Los Angeles, California • Washington D.C., District of Columbia • West Des Moines, Iowa + 4 more

Conditions: Psoriasis
Interventions: Cyclosporine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Plaque-type Psoriasis
Interventions: Skin biopsies; Procedure
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: New Orleans, Louisiana • East Windsor, New Jersey • Philadelphia, Pennsylvania + 1 more

Conditions: Plaque Psoriasis
Interventions: Zasocitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 11
States / cities: Chula Vista, California • Fountain Valley, California • Hialeah, Florida + 8 more

Conditions: Psoriasis
Interventions: GR-MD-02; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Safety and Efficacy of IDP-122 in Participants With Plaque Psoriasis

Role of Chemokine and Chemokine Receptor in Psoriasis

Immunologic Response to Secukinumab in Plaque Psoriasis

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

A Long-term Safety Study of Infliximab (Remicade)

Study to Evaluate Broadlumab vs Placebo and Ustekinumab

Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.

An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)

Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Safety and Tolerability of Repeat Courses of IM Alefacept

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

The Effectiveness of Lower Cyclosporine Doses for Psoriasis

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis